(Q24235589)

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Strontium and samarium therapy for bone metastases from prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Systemic radionuclide therapy in pain palliation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Palliative radiotherapy trials for bone metastases: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Radioisotopes for the palliation of metastatic bone cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Calcitonin for metastatic bone pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Palliative therapy with bone seeking radiopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Radiotherapy for the palliation of painful bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Bone metastases: pathophysiology and management policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Bisphosphonates for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Chemotherapy for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Bisphosphonates for the relief of pain secondary to bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Bisphosphonates for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Radioisotopes for metastatic bone pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Special Topics in Statistics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Interpreting Results and Drawing Conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

7 January 2021

EANM procedure guideline for treatment of refractory metastatic bone pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

7 January 2021

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

7 January 2021

A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

7 January 2021

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003347.PUB2

7 January 2021

Systemic bone-seeking radionuclides for palliation of painful osseous metastases: current concepts

1 reference

COCI

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003347.PUB2

Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma

9 February 2024

1 reference

COCI

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003347.PUB2

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

9 February 2024

1 reference

COCI

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003347.PUB2

10.1002/14651858.CD003347.PUB2

9 February 2024

Identifiers

DOI

0 references

Fatcat ID

release_iiq2qr3jifh2joee7gceepgzju

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iiq2qr3jifh2joee7gceepgzju

24 November 2022